Polymorphisms of the Matrix Metalloproteinase Genes are Associated with Acute Ischemic Stroke in Chinese Han Population

References

• Claiborne JS, Elm jordan J, Donald EJ, et al. Time course for benefit and risk of clopidogrel and aspirin after acute transient ischemic attack and minor ischemic. Stroke. 2019;(8). doi:10.1161/CIRCULATIONAHA.119.040713
   Google Scholar
• Araki Y, Kumakura H, Kanai H, et al. Prevalence and risk factors for cerebral infarction and carotid artery stenosis in peripheral arterial disease. Atherosclerosis. 2012;223(2):473–477. doi:10.1016/j.atherosclerosis.2012.05.019
   PubMed Web of Science ®Google Scholar
• Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology. 2013;(6). doi:10.1152/physiol.00029.2013
   PubMed Web of Science ®Google Scholar
• Changjun Y, Hawkins Kimberly E, Sylvain D, et al. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. American journal of physiology. Cell Physiol. 2019;316(2):C135–C153. doi:10.1152/ajpcell.00136.2018
   PubMed Web of Science ®Google Scholar
• Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke. 2003;2003(9):2165–2170. doi:10.1161/01.STR.0000088062.86084.F2
   Google Scholar
• Ren X, Hu H, Farooqi I, et al. Blood substitution therapy rescues the brain of mice from ischemic damage. Nat Commun. 2020;2020(1):4087–4090. doi:10.1038/s41467-020-17930-x
   Google Scholar
• Domenico I, Betti G, Patrizia N, et al. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death. Stroke. 2013;(10):2901–2903. doi:10.1161/STROKEAHA.113.002274
   PubMed Web of Science ®Google Scholar
• Zhang S, An Q, Wang T, et al. Autophagy- and MMP-2/9-mediated reduction and redistribution of ZO-1 contribute to hyperglycemia-increased blood-brain barrier permeability during early reperfusion in stroke. Neuroscience. 2018;1(377):126–137. doi:10.1016/j.neuroscience.2018.02.035
   Google Scholar
• Burggraf D, Vosko MR, Schubert M, et al. Different therapy options protecting microvasculature after experimental cerebral ischemia and reperfusion. Thrombos Haemostas. 2010;(5):891–900. doi:10.1160/TH09-07-0500
   PubMed Web of Science ®Google Scholar
• Yasuhiro S, Nobuo N, Kasumi Y, et al. Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. Blood. 2009;(15):3352–3358. doi:10.1182/blood-2009-02-203919
   Web of Science ®Google Scholar
• Liu M, He M. 中国急性缺血性脑卒中诊治指南2014 [Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014]. Chinese Journal of Neurology. 2015 : 48: (04) 246–257. Chinese.
   Google Scholar
• Knox JB, Sukhova GK, Whittemore AD, et al. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation. 1997;(1):205–212. doi:10.1161/01.cir.95.1.205
   PubMed Web of Science ®Google Scholar
• Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol. 2013;(9):649–665. doi:10.1038/nri3499
   PubMed Web of Science ®Google Scholar
• Loeffek S, Schilling O, Franzke C-W. Biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011;(1):191–208. doi:10.1183/09031936.00146510
   PubMed Web of Science ®Google Scholar
• Lorenzano S, Rost NS, Khan M, et al. Early molecular oxidative stress biomarkers of ischemic penumbra in acute stroke. Neurology. 2013;13:32. doi:10.1212/WNL.0000000000008158
   PubMedGoogle Scholar
• Jara CM, Natalia C, Muiño E, et al. Causal effect of MMP-1 (Matrix Metalloproteinase-1), MMP-8, and MMP-12 levels on ischemic stroke: a Mendelian randomization study. Stroke. 2021;2021:E316–E320. doi:10.1161/STROKEAHA.120.033041
   Google Scholar
• Zhang L. Connectivity map identifies luteolin as a treatment option of ischemic stroke by inhibiting MMP9 and activation of the PI3K/ Akt signaling pathway. Exp Mol Med. 2019;51(S2). doi:10.1038/s12276-019-0229-z
   Google Scholar
• Lishuai F, Chaoran D, Yuguo X, et al. Neutrophil-like cell-membrane-coated nanozyme therapy for ischemic brain damage and long-term neurological functional recovery. ACS Nano. 2021;15(2):2263–2280. doi:10.1021/acsnano.0c07973
   PubMed Web of Science ®Google Scholar
• Johnston KC, Bruno A, Pauls Q, et al. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial. JAMA. 2019;2019(4):326–335. doi:10.1001/jama.2019.9346
   Google Scholar
• Zhong C, Bu X, Xu T, et al. Serum matrix metalloproteinase-9 and cognitive impairment after acute ischemic stroke. J Am Heart Assoc. 2018;7(1):e007776. doi:10.1161/JAHA.117.007776
   PubMed Web of Science ®Google Scholar
• Maestrini I, Tagzirt M, Gautier S, et al. Analysis of the association of MPO and MMP-9 with stroke severity and outcome Cohort study. Neurology. 2020;2020(1):E97–E108. doi:10.1212/WNL.0000000000009179
   Google Scholar
• Sherif H, Mohammed A, Sally E-S, et al. Matrix metalloprotease 3 exacerbates hemorrhagic transformation and worsens functional outcomes in hyperglycemic stroke. Stroke. 2016;47(3):843–851. doi:10.1161/STROKEAHA.115.011258
   PubMed Web of Science ®Google Scholar
• Maithili S, Eunice S, Maria D, et al. The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain. 2012;(135):3251–3264. doi:10.1093/brain/aws178
   PubMedGoogle Scholar